Characteristics of patients undergoing ASCT
| Patients’ characteristics . | Overall (n = 136) . | LEVO-group (n = 38) . | NO-LEVO-group (n = 98) . | P value . |
|---|---|---|---|---|
| Baseline | ||||
| Age at ASCT, y, median (IQR) | 59 (52-66) | 63 (50-66) | 58 (52-65) | .86 |
| Male sex | 87 (64%) | 24 (63.2%) | 63 (64.3%) | .90 |
| Total number of ASCT for patient | .66 | |||
| First ASCT | 104 (76.5%) | 30 (78.9%) | 74 (75.5%) | |
| Second ASCT | 30 (22%) | 8 (21.1%) | 22 (22.5%) | |
| Third ASCT | 2 (1.5%) | 0 (0%) | 2 (2%) | |
| Diagnosis | .82 | |||
| Myeloid disorders | 4 (2.9%) | 1 (2.6%) | 3 (3.1%) | |
| Lymphoid disorders | 127 (93.4%) | 35 (92.1%) | 92 (93.8%) | |
| Other disorders | 5 (3.7%) | 2 (5.3%) | 3 (3.1%) | |
| Disease status at ASCT | .46 | |||
| Complete response | 86 (63.2%) | 21 (55.2%) | 65 (66.3%) | |
| Active disease | 45 (33.1%) | 15 (39.5%) | 30 (30.6%) | |
| Other | 5 (3.7%) | 2 (5.3%) | 3 (3.1%) | |
| Ongoing line of therapy | .75 | |||
| First line | 104 (76.5%) | 29 (76.3%) | 75 (76.5%) | |
| Second line | 21 (15.4%) | 5 (13.2%) | 16 (16.3%) | |
| Third line | 11 (8.1%) | 4 (10.5%) | 7 (7.2%) | |
| Conditioning chemotherapy | .75 | |||
| Myeloablative | 120 (88.2%) | 33 (86.8%) | 87 (88.8%) | |
| Reduced intensity | 16 (11.8%) | 5 (13.2%) | 11 (11.2%) | |
| ANC <500 cells/mm3 ≥ 7 d | 0 (0%) | 0 (0%) | 0 (0%) | - |
| MDR-GNB rectal carrier ≤30 d before ASCT | 1 (0.7%) | 0 (0%) | 1 (1%) | .53 |
| Antibiotics ≤90 d before ASCT | 12 (8.8%) | 0 (0%) | 12 (12.2%) | .02 |
| Follow-up | ||||
| Follow-up, d, median (IQR) | 318 (153-596) | 758 (188-964) | 256 (149-523) | .0001 |
| ANC engraftment | 136 (100%) | 38 (100%) | 98 (100%) | - |
| Time to engraftment, d, median (IQR) | 11 (10-11.5) | 11 (10-11) | 11 (10-12) | .82 |
| Relapse | 22 (16.2%) | 10 (26.3%) | 12 (12.2%) | .05 |
| Overall death | 13 (9.6%) | 7 (18.4%) | 6 (6.1%) | .03 |
| Causes of death | .13 | |||
| Disease | 8 (5.9%) | 5 (13.2%) | 3 (3.1%) | |
| IRM | 3 (2.2%) | 1 (2.6%) | 2 (2%) | |
| Others | 2 (1.5%) | 1 (2.6%) | 1 (1%) |
| Patients’ characteristics . | Overall (n = 136) . | LEVO-group (n = 38) . | NO-LEVO-group (n = 98) . | P value . |
|---|---|---|---|---|
| Baseline | ||||
| Age at ASCT, y, median (IQR) | 59 (52-66) | 63 (50-66) | 58 (52-65) | .86 |
| Male sex | 87 (64%) | 24 (63.2%) | 63 (64.3%) | .90 |
| Total number of ASCT for patient | .66 | |||
| First ASCT | 104 (76.5%) | 30 (78.9%) | 74 (75.5%) | |
| Second ASCT | 30 (22%) | 8 (21.1%) | 22 (22.5%) | |
| Third ASCT | 2 (1.5%) | 0 (0%) | 2 (2%) | |
| Diagnosis | .82 | |||
| Myeloid disorders | 4 (2.9%) | 1 (2.6%) | 3 (3.1%) | |
| Lymphoid disorders | 127 (93.4%) | 35 (92.1%) | 92 (93.8%) | |
| Other disorders | 5 (3.7%) | 2 (5.3%) | 3 (3.1%) | |
| Disease status at ASCT | .46 | |||
| Complete response | 86 (63.2%) | 21 (55.2%) | 65 (66.3%) | |
| Active disease | 45 (33.1%) | 15 (39.5%) | 30 (30.6%) | |
| Other | 5 (3.7%) | 2 (5.3%) | 3 (3.1%) | |
| Ongoing line of therapy | .75 | |||
| First line | 104 (76.5%) | 29 (76.3%) | 75 (76.5%) | |
| Second line | 21 (15.4%) | 5 (13.2%) | 16 (16.3%) | |
| Third line | 11 (8.1%) | 4 (10.5%) | 7 (7.2%) | |
| Conditioning chemotherapy | .75 | |||
| Myeloablative | 120 (88.2%) | 33 (86.8%) | 87 (88.8%) | |
| Reduced intensity | 16 (11.8%) | 5 (13.2%) | 11 (11.2%) | |
| ANC <500 cells/mm3 ≥ 7 d | 0 (0%) | 0 (0%) | 0 (0%) | - |
| MDR-GNB rectal carrier ≤30 d before ASCT | 1 (0.7%) | 0 (0%) | 1 (1%) | .53 |
| Antibiotics ≤90 d before ASCT | 12 (8.8%) | 0 (0%) | 12 (12.2%) | .02 |
| Follow-up | ||||
| Follow-up, d, median (IQR) | 318 (153-596) | 758 (188-964) | 256 (149-523) | .0001 |
| ANC engraftment | 136 (100%) | 38 (100%) | 98 (100%) | - |
| Time to engraftment, d, median (IQR) | 11 (10-11.5) | 11 (10-11) | 11 (10-12) | .82 |
| Relapse | 22 (16.2%) | 10 (26.3%) | 12 (12.2%) | .05 |
| Overall death | 13 (9.6%) | 7 (18.4%) | 6 (6.1%) | .03 |
| Causes of death | .13 | |||
| Disease | 8 (5.9%) | 5 (13.2%) | 3 (3.1%) | |
| IRM | 3 (2.2%) | 1 (2.6%) | 2 (2%) | |
| Others | 2 (1.5%) | 1 (2.6%) | 1 (1%) |